--- title: "Aligos Therapeutics, Inc. (ALGS.US)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/ALGS.US.md" symbol: "ALGS.US" name: "Aligos Therapeutics, Inc." industry: "Biotechnology" datetime: "2026-03-13T23:42:39.540Z" locales: - [en](https://longbridge.com/en/quote/ALGS.US.md) - [zh-CN](https://longbridge.com/zh-CN/quote/ALGS.US.md) - [zh-HK](https://longbridge.com/zh-HK/quote/ALGS.US.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/ALGS.US.md) | [繁體中文](https://longbridge.com/zh-HK/quote/ALGS.US.md) # Aligos Therapeutics, Inc. (ALGS.US) ## Company Overview Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. | Item | Detail | |------|--------| | Industry | Biotechnology | | Exchange | US Market | | Website | [www.aligos.com](https://www.aligos.com) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: D > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-03-13T04:30:17.000Z **Overall: D (0.73)** **Industry**: Biotechnology | Metric | Value | |--------|-------| | Industry Ranking | 297 / 404 | | Industry Median | C | | Industry Average | C | - **Style**: Value - Stocks where the company's main business is in a mature stage. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: D #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | -44.59% | | | Net Profit YoY | 81.56% | | | P/B Ratio | 0.86 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 45851649.87 | | | Revenue | 2186000.00 | | #### Multi Score Score: D | Indicator | Value | Rating | |-----------|-------|--------| | ROE | -196.92% | E | | Profit Margin | -1106.72% | E | | Gross Margin | -3077.17% | E | | Revenue YoY | -44.59% | E | | Net Profit YoY | 81.56% | A | | Total Assets YoY | 26.31% | A | | Net Assets YoY | 284.81% | A | | Cash Flow Margin | -9.04% | D | | OCF YoY | -44.59% | E | | Turnover | 0.03 | E | | Gearing Ratio | 39.52% | C | ```chart-data:radar { "title": "Longbridge Financial Score - Aligos Therapeutics, Inc.", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "-44.59%", "rating": "" }, { "name": "Net Profit YoY", "value": "81.56%", "rating": "" }, { "name": "P/B Ratio", "value": "0.86", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "45851649.87", "rating": "" }, { "name": "Revenue", "value": "2186000.00", "rating": "" } ] }, { "name": "Multi Score", "grade": "D", "indicators": [ { "name": "ROE", "value": "-196.92%", "rating": "E" }, { "name": "Profit Margin", "value": "-1106.72%", "rating": "E" }, { "name": "Gross Margin", "value": "-3077.17%", "rating": "E" }, { "name": "Revenue YoY", "value": "-44.59%", "rating": "E" }, { "name": "Net Profit YoY", "value": "81.56%", "rating": "A" }, { "name": "Total Assets YoY", "value": "26.31%", "rating": "A" }, { "name": "Net Assets YoY", "value": "284.81%", "rating": "A" }, { "name": "Cash Flow Margin", "value": "-9.04%", "rating": "D" }, { "name": "OCF YoY", "value": "-44.59%", "rating": "E" }, { "name": "Turnover", "value": "0.03", "rating": "E" }, { "name": "Gearing Ratio", "value": "39.52%", "rating": "C" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | -1.90 | 244/404 | - | - | - | | PB | 0.86 | 69/404 | 0.74 | 0.59 | 0.42 | | PS (TTM) | 20.98 | 200/404 | 20.37 | 16.66 | 13.43 | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A | | 02 | Stoke Therapeutics (STOK.US) | A | A | B | A | B | A | | 03 | MiMedx (MDXG.US) | A | B | A | B | B | A | | 04 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A | | 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A | ## Institutional View ### Analyst Rating Distribution > As of 2026-03-11T04:00:00.000Z Total Analysts: **5** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 4 | 80% | | Overweight | 1 | 20% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 7.57 | | Highest Target | 175.00 | | Lowest Target | 20.00 | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ALGS.US/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ALGS.US/norm.md) - [Related News](https://longbridge.com/en/quote/ALGS.US/news.md) - [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ALGS.US/filings.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**